Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2015 Jul 15;25(14):2818-23. doi: 10.1016/j.bmcl.2015.04.107. Epub 2015 May 11.

Discovery of a new chemical series of BRD4(1) inhibitors using protein-ligand docking and structure-guided design.

Author information

1
Albany Molecular Research (AMRI), 26 Corporate Circle, PO Box 15098, Albany, NY 12212-5098, USA.
2
JFQuinn Consulting, 113 Jay St., Albany, NY 12210, USA.
3
Zenith Epigenetics Corp., Suite 300, 4820 Richard Road SW, Calgary, Alberta T3E 6L1, Canada.
4
Xtal BioStructures, Inc., 12 Michigan Dr., Natick, MA 01760, USA.
5
Albany Molecular Research (AMRI), 26 Corporate Circle, PO Box 15098, Albany, NY 12212-5098, USA. Electronic address: douglas.kitchen@amriglobal.com.

Abstract

Bromodomains are key transcriptional regulators that are thought to be druggable epigenetic targets for cancer, inflammation, diabetes and cardiovascular therapeutics. Of particular importance is the first of two bromodomains in bromodomain containing 4 protein (BRD4(1)). Protein-ligand docking in BRD4(1) was used to purchase a small, focused screening set of compounds possessing a large variety of core structures. Within this set, a small number of weak hits each contained a dihydroquinoxalinone ring system. We purchased other analogs with this ring system and further validated the new hit series and obtained improvement in binding inhibition. Limited exploration by new analog synthesis showed that the binding inhibition in a FRET assay could be improved to the low μM level making this new core a potential hit-to-lead series. Additionally, the predicted geometries of the initial hit and an improved analog were confirmed by X-ray co-crystallography with BRD4(1).

KEYWORDS:

BRD4(1); Bromodomain inhibitors; Hit triage; Protein-ligand docking; Virtual screening

PMID:
26022843
DOI:
10.1016/j.bmcl.2015.04.107
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center